Keywords: سرطان پروستات مقاوم در برابر کاتتراسیون; prostatic neoplasms; prostate-specific antigen; neoplasm recurrence; local; prostatectomy; prognosis; ACM; all cause mortality; BCR; biochemical recurrence; CRPC; castration resistant prostate cancer; ePSADT; early PSADT; PCSM; prostate cancer specific mo
مقالات ISI سرطان پروستات مقاوم در برابر کاتتراسیون (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: سرطان پروستات مقاوم در برابر کاتتراسیون; Castration resistant prostate cancer; Cancer costs; Castration resistant therapies; Health economics; Palliative care; Quality of life;
Keywords: سرطان پروستات مقاوم در برابر کاتتراسیون; prostatic neoplasms; castration-resistant; subcutaneous fat; prognosis; tomography; x-ray computed; mortality; ADT; androgen deprivation therapy; ARAT; androgen receptor axis targeted; BMI; body mass index; CCI; Charlson Comorbidity Index; CRPC; castratio
Keywords: سرطان پروستات مقاوم در برابر کاتتراسیون; ARSIs; androgen receptor signaling inhibitors; AA; abiraterone acetate; AR; androgen receptor; BPH; benign prostatic hyperplasia; CNV; copy number variation; CRPC; castration resistant prostate cancer; CTC; circulating tumor cells; ctDNA; cell-free circul
Keywords: سرطان پروستات مقاوم در برابر کاتتراسیون; PC; prostate cancer; mPC; metastatic prostate cancer; ADT; androgen deprivation therapy; CRPC; castration resistant prostate cancer; mCRPC; metastatic CRPC; SNP; single nucleotide polymorphism; CNV; copy number variation; AR; androgen receptor; CTC; circu
Keywords: سرطان پروستات مقاوم در برابر کاتتراسیون; Androgens; Intracrinology; Steroid biosynthesis; Hormone-dependent cancer; Testosterone; 11-oxygenated androgens; 11KA4; 11-keto-androstenedione; 11KDHT; 11-keto-5α-dihydrotestosterone; 11KT; 11-keto-testosterone; 11OHA4; 11β-hydroxy-androstenedione; 11
Keywords: سرطان پروستات مقاوم در برابر کاتتراسیون; ADT; Androgen deprivation therapy; AR; Androgen receptor; CRPC; Castration resistant prostate cancer; DHT; Dihydrotestosterone; EGF; Epidermal growth factor; EMT; Epithelial mesenchymal transition; ERβ; Estrogen receptor β; FGF; Fibroblast growth factor
Keywords: سرطان پروستات مقاوم در برابر کاتتراسیون; AR; androgen receptor protein; BHK; baby hamster kidney; CMV IE; immediate early promoter of cytomegalovirus; CRPC; castration resistant prostate cancer; CYP17; 17α-hydroxy/17,20-lyase; DAPI; 4â²,6-diamidino-2-phenylindole; DBD; DNA-binding domain; DHT;
Keywords: سرطان پروستات مقاوم در برابر کاتتراسیون; Castration resistant prostate cancer; Androgen conjugates; Androgen diols; Enzymatic synthesis; Picolinic acid derivatization; LC-ESI-MS/MS;
Keywords: سرطان پروستات مقاوم در برابر کاتتراسیون; prostatic neoplasms; immunotherapy; ADT; androgen deprivation therapy; APC; antigen presenting cell; CRPC; castration resistant prostate cancer; GM-CSF; granulocyte-macrophage colony-stimulating factor; mCRPC; metastatic castration resistant prostate canc
Keywords: سرطان پروستات مقاوم در برابر کاتتراسیون; prostatic neoplasms; neoplasm staging; practice guidelines as topic; guideline adherence; ADT; androgen deprivation therapy; APC; advanced prostate cancer; CRPC; castration resistant prostate cancer; EMR; electronic medical record; IUOGP; integrated urolo
Keywords: سرطان پروستات مقاوم در برابر کاتتراسیون; prostatic neoplasms; testosterone; prostate-specific antigen; leuprolide; mortality; ADT; androgen deprivation therapy; CAD; continuous androgen deprivation; CRPC; castration resistant prostate cancer; CSS; cause specific survival; IAD; intermittent andro
Keywords: سرطان پروستات مقاوم در برابر کاتتراسیون; Androgen receptor; Bicalutamide; Castration resistant prostate cancer; Estrogen receptor; Prostate; Raloxifene;
Keywords: سرطان پروستات مقاوم در برابر کاتتراسیون; Prostate cancer; Androgen; Signaling pathways; Castration resistant prostate cancer;
Keywords: سرطان پروستات مقاوم در برابر کاتتراسیون; Mismatch repair; Castration resistant prostate cancer; MLH1; MSH2; MSH6; PMS2;
Keywords: سرطان پروستات مقاوم در برابر کاتتراسیون; Androgen; Androgen receptor; Androgen deprivation therapy; Castration resistant prostate cancer;
Keywords: سرطان پروستات مقاوم در برابر کاتتراسیون; Prostate cancer; Castration resistant prostate cancer; Enzalutamide; Abiraterone; Docetaxel; Drug resistance;
Keywords: سرطان پروستات مقاوم در برابر کاتتراسیون; Castration resistant prostate cancer; Bone metastasis; Skeletal related event; New generation hormonal agents; Chemotherapy; Bone-targeted therapy
Keywords: سرطان پروستات مقاوم در برابر کاتتراسیون; Enzalutamide; Prostate cancer; MDV3100; castration resistant prostate cancer; AR targeted therapies
Keywords: سرطان پروستات مقاوم در برابر کاتتراسیون; Androgens; Castration resistant prostate cancer; Liquid chromatography tandem mass spectrometry;
Keywords: سرطان پروستات مقاوم در برابر کاتتراسیون; prostatic neoplasms; castration-resistant; ADT; androgen deprivation therapy; AUA; American Urological Association; CRPC; castration resistant prostate cancer; FDA; Food and Drug Administration; mCRPC; metastatic castration resistant prostate cancer; PSA;
Keywords: سرطان پروستات مقاوم در برابر کاتتراسیون; Castration resistant prostate cancer; Cabazitaxel; Prostate-specific antigen; Chemotherapy; Cytotoxic agents; Survival rate;
Keywords: سرطان پروستات مقاوم در برابر کاتتراسیون; Castration resistant prostate cancer; Molecular biology; Androgen receptor; Novel therapeutics;
Keywords: سرطان پروستات مقاوم در برابر کاتتراسیون; Castration resistant prostate cancer; CRPC; Elderly; Abiraterone; Cabazitaxel; Sipuleucel-T; Enzalutamide; Alpharadin; Denosumab;
Keywords: سرطان پروستات مقاوم در برابر کاتتراسیون; Angiogenesis; Castration resistant prostate cancer; Vascular endothelial growth factor; Bevacizumab; Sunitinib; Cabozantinib;
11-Oxygenated androgen precursors are the preferred substrates for aldo-keto reductase 1C3 (AKR1C3): Implications for castration resistant prostate cancer
Keywords: سرطان پروستات مقاوم در برابر کاتتراسیون; 11-Oxygenated androgens; Aldo-keto reductase 1C3; 17β-Hydroxysteroid dehydrogenase type 2; 11-Ketotestosterone; Castration resistant prostate cancer;
eIF4E Phosphorylation in Prostate Cancer
Keywords: سرطان پروستات مقاوم در برابر کاتتراسیون; eIF4E; eukaryotic translation initiation factor 4E; mTOR; mammalian target of rapamycin; PCa; prostate cancer; Mnk; mitogen activated protein kinase interacting protein kinase; ADT; androgen deprivation therapy; MAPK; mitogen-activated protein kinase; CRP
The efficacy and safety comparison of docetaxel, cabazitaxel, estramustine, and mitoxantrone for castration-resistant prostate cancer: A network meta-analysis
Keywords: سرطان پروستات مقاوم در برابر کاتتراسیون; Castration resistant prostate cancer; Chemothreapy; Docetaxel; Estramustine; Cabazitaxel; Mitoxantrone; Network meta-analysis;
Pharmacogenetics of androgen signaling in prostate cancer: Focus on castration resistance and predictive biomarkers of response to treatment
Keywords: سرطان پروستات مقاوم در برابر کاتتراسیون; Castration resistant prostate cancer; Tumor heterogeneity; Androgen receptor; Treatment resistance; Predictive biomarkers;
Adult UrologyOncology: Prostate/Testis/Penis/UrethraAR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate
Keywords: سرطان پروستات مقاوم در برابر کاتتراسیون; prostatic neoplasms; castration-resistant; neoplasm metastasis; receptors; androgen; biomarkers; tumor; abiraterone; ALP; alkaline phosphatase; AR; androgen receptor; CRPC; castration resistant prostate cancer; Ct; cycle threshold; CTC; circulating tumor
Lipid-oligonucleotide conjugates improve cellular uptake and efficiency of TCTP-antisense in castration-resistant prostate cancer
Keywords: سرطان پروستات مقاوم در برابر کاتتراسیون; Antisense oligonucleotides; TCTP; Castration resistant prostate cancer; Lipid modification; Drug delivery;
Original ArticleInduction of neuroendocrine differentiation in castration resistant prostate cancer cells by adipocyte differentiation-related protein (ADRP) delivered by exosomes
Keywords: سرطان پروستات مقاوم در برابر کاتتراسیون; Adipocyte differentiation-related protein; Castration resistant prostate cancer; Adiposome; Neuroendocrine differentiation; Exosomes;
Mini-reviewTargeting androgen receptor versus targeting androgens to suppress castration resistant prostate cancer
Keywords: سرطان پروستات مقاوم در برابر کاتتراسیون; AR degradation; AR splicing variant; Anti-androgen; Castration resistant prostate cancer; Combination therapy;
Specificity of anti-prostate cancer CYP17A1 inhibitors on androgen biosynthesis
Keywords: سرطان پروستات مقاوم در برابر کاتتراسیون; CYP17A1; Orteronel; Abiraterone; CYP21A2; PCOS; Premature adrenarche; Castration resistant prostate cancer;
A Whole Blood Assay for AR-V7 and ARv567es in Patients with Prostate Cancer
Keywords: سرطان پروستات مقاوم در برابر کاتتراسیون; prostatic neoplasms; receptors; androgen; blood; biomarkers; tumor; protein isoforms; AR-FL; full-length androgen receptor; CRPC; castration resistant prostate cancer; CTC; circulating tumor cell; EMT; epithelial-to-mesenchymal transition; EpCAM; epitheli
Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer
Keywords: سرطان پروستات مقاوم در برابر کاتتراسیون; Abiraterone; Castration resistant prostate cancer; Cross-resistance; Docetaxel; Enzalutamide;
Mechanisms of drug resistance that target the androgen axis in castration resistant prostate cancer (CRPC)
Keywords: سرطان پروستات مقاوم در برابر کاتتراسیون; ADMET; absorption distribution, metabolism, elimination and toxicity; Î4-A; 4-androstene-3,17-dione; Î5-Adiol; 5-androstene-3β,17β-diol; 3α-Adiol; 5α-androstane-3α,17β-diol; Adione; 5α-androstane-3,17-dione; ADT; androgen deprivation therapy; AR;
Screening baccharin analogs as selective inhibitors against type 5 17β-hydroxysteroid dehydrogenase (AKR1C3)
Keywords: سرطان پروستات مقاوم در برابر کاتتراسیون; Castration resistant prostate cancer; Androgen; Androgen receptor signaling
Inhibition of LSD1 by Pargyline inhibited process of EMT and delayed progression of prostate cancer in vivo
Keywords: سرطان پروستات مقاوم در برابر کاتتراسیون; LSD1; Pargyline; Epithelial-mesenchymal transition; Androgen deprivation therapy; Castration resistant prostate cancer;
Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone
Keywords: سرطان پروستات مقاوم در برابر کاتتراسیون; Abiraterone; Enzalutamide; Castration resistant prostate cancer; Hormone therapy; Androgen receptor targeting;
Next-generation steroidogenesis inhibitors, dutasteride and abiraterone, attenuate but still do not eliminate androgen biosynthesis in 22RV1 cells in vitro
Keywords: سرطان پروستات مقاوم در برابر کاتتراسیون; DHEA; dehydroepiandrosterone; DHT; dihydrotestosterone; LHRH; luteinizing hormone releasing hormone; LH; luteinizing hormone; AR; androgen receptor; CRPC; castration resistant prostate cancer; PSA; prostate specific antigen; SRD5A1/2; 5-alpha-reductase is
Development, validation and application of a stable isotope dilution liquid chromatography electrospray ionization/selected reaction monitoring/mass spectrometry (SID-LC/ESI/SRM/MS) method for quantification of keto-androgens in human serum
Keywords: سرطان پروستات مقاوم در برابر کاتتراسیون; A; androsterone; Adione; 5α-androstane-3,17-dione; Î4-AD; Î4-androstene-3,17-dione; ADT; androgen deprivation therapy; CD-FBS; charcoal dextran stripped fetal bovine serum; CRPC; castration resistant prostate cancer; CV; coefficient of variation; DHEA;
Targeted disruption of the p160 coactivator interface of androgen receptor (AR) selectively inhibits AR activity in both androgen-dependent and castration-resistant AR-expressing prostate cancer cells
Keywords: سرطان پروستات مقاوم در برابر کاتتراسیون; ANOVA; analysis of variance; AR; androgen receptor; ARDH; AR DNA and hormone-binding domains; ARNTD; AR amino terminus and DNA-binding domain; ATCC; American Type Culture Collection; CARM-1; coactivator associated arginine methyltransferase-1; CRPC; castr
Metabolic and Prostate-Specific Antigen Response After Abiraterone Acetate Withdrawal: A New Clinical Scenario for Castration-Resistant Prostate Cancer?
Keywords: سرطان پروستات مقاوم در برابر کاتتراسیون; Abiraterone; Castration resistant prostate cancer; Choline positron emission tomography; Withdrawal response;
Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: Implications for prior therapy in clinical trials
Keywords: سرطان پروستات مقاوم در برابر کاتتراسیون; Docetaxel; Ketoconazole; Metastatic; Castration resistant prostate cancer
Discovery of 3-aryloxy-lactam analogs as potent androgen receptor full antagonists for treating castration resistant prostate cancer
Keywords: سرطان پروستات مقاوم در برابر کاتتراسیون; Androgen receptor; AR antagonist; Prostate cancer; Ligand efficiency; Polar surface area; PSA; Castration resistant prostate cancer; CRPC; LBD; NHR;
Transcript Levels of Androgen Receptor Variant AR-V1 or AR-V7 Do Not Predict Recurrence in Patients with Prostate Cancer at Indeterminate Risk for Progression
Keywords: سرطان پروستات مقاوم در برابر کاتتراسیون; prostate; prostatic neoplasms; receptors, androgen; neoplasm recurrence, local; prostate-specific antigen; AR; androgen receptor; bDNA; branched chain DNA; CRPC; castration resistant prostate cancer; ERG; Ets related gene; FFPE; formalin fixed, paraffin e
Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro)
Keywords: سرطان پروستات مقاوم در برابر کاتتراسیون; Bisphosphonates; Bone metastases; Castration Resistant Prostate Cancer; Docetaxel; Risedronate;
Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenografts
Keywords: سرطان پروستات مقاوم در برابر کاتتراسیون; Castration resistant prostate cancer; Androgen synthesis; Progesterone
Innovations and Challenges in Prostate Cancer: Summary Statement for the 6th Cambridge Conference
Keywords: سرطان پروستات مقاوم در برابر کاتتراسیون; prostate; prostatic neoplasms; clinical conference [publication type]; ADT; androgen deprivation therapy; CRPC; castration resistant prostate cancer; EBRT; external beam radiation therapy; PSA; prostate specific antigen; PSADT; PSA doubling time; RP; radi